Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 13/20 | 0.61 |
| ▸ | SRC | P12931 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162693 | 1.00 | CFTR (0.61) | CFTRSRCEGFRKDRRET | |
| SCHEMBL20162697 | 1.00 | CFTR (0.61) | CFTRSRCEGFRKDRRET | |
| SCHEMBL30036850 | 1.00 | CFTR (0.61) | CFTRSRCEGFRKDRRET | |
| SCHEMBL20163079 | 0.94 | CFTR (0.54) | CFTRSRCEGFREIF2AK3 | |
| SCHEMBL20163077 | 0.94 | CFTR (0.54) | CFTRSRCEGFREIF2AK3 | |
| SCHEMBL30037224 | 0.94 | CFTR (0.54) | CFTRSRCEGFREIF2AK3 | |
| SCHEMBL30036359 | 0.94 | CFTR (0.54) | CFTRSRCEGFREIF2AK3 | |
| SCHEMBL20162642 | 0.91 | CFTR (0.52) | CFTRSRC | |
| SCHEMBL20162643 | 0.91 | CFTR (0.52) | CFTRSRC | |
| SCHEMBL20162803 | 0.91 | CFTR (0.52) | CFTRSRCEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4424311-A2 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3541390-B1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | CFTR 1/4885SRC 3551/4885EGFR 1738/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | CFTR 1/4885SRC 2589/4885EGFR 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.